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Desmoplakin (DP) is an obligate component of desmosomes, intercellular adhesive junctions that maintain the integrity 
of the epidermis and myocardium. Mutations in DP can cause cardiac and cutaneous disease, including arrhythmogenic 
cardiomyopathy (ACM), an inherited disorder that frequently results in deadly arrhythmias. Conduction defects in ACM are 
linked to the remodeling and functional interference with Cx43-based gap junctions that electrically and chemically couple 
cells. How DP loss impairs gap junctions is poorly understood. We show that DP prevents lysosomal-mediated degradation of 
Cx43. DP loss triggered robust activation of ERK1/2–MAPK and increased phosphorylation of S279/282 of Cx43, which signals 
clathrin-mediated internalization and subsequent lysosomal degradation of Cx43. RNA sequencing revealed Ras-GTPases as 
candidates for the aberrant activation of ERK1/2 upon loss of DP. Using a novel Ras inhibitor, Ras/Rap1-specific peptidase 
(RRSP), or K-Ras knockdown, we demonstrate restoration of Cx43 in DP-deficient cardiomyocytes. Collectively, our results 
reveal a novel mechanism for the regulation of the Cx43 life cycle by DP in cardiocutaneous models.
Desmoplakin maintains gap junctions by inhibiting 
Ras/MAPK and lysosomal degradation of connexin-43
Chen Yuan Kam1, Adi D. Dubash1, Elisa Magistrati3, Simona Polo3,4, Karla J.F. Satchell5,8, Farah Sheikh6, Paul D. Lampe7, and 
Kathleen J. Green1,2,8
Introduction
Maintenance of tissue homeostasis and integrity is achieved 
through highly specialized membrane–cytoskeleton attachment 
sites. The most prominent of these in the epidermis and myo-
cardium are desmosomes, which are cadherin-based junctional 
complexes that tether the intermediate filament (IF) cytoskele-
ton to sites of cell–cell adhesion (Leung et al., 2002; Green and 
Simpson, 2007). In both epithelial and cardiac cells, desmosomes 
are structurally and functionally associated with actin-associated 
adherens junctions, which organize the cortical actin cytoskele-
ton, and connexin-containing gap junctions, which are pore-like 
structures that allow for the passage of small molecules and ions 
between two neighboring cells (Saez et al., 2003; Laird, 2006; 
Goodenough and Paul, 2009). In cardiomyocytes, close associa-
tion between junctions is facilitated by intercalated discs (IDs), 
which are present where cardiomyocytes meet end to end and 
serve to integrate force transmission and electrical coupling in 
the heart (Forbes and Sperelakis, 1985). The ID in adult mam-
mals is further specialized to form the area composita, in which 
adherens junction and desmosome components are intermixed, 
further stabilizing the junction (Goossens et al., 2007; Pieperhoff 
and Franke, 2007; Pieperhoff et al., 2008).
The desmosomal component that physically links the trans-
membrane desmosomal cadherin complex to the IF cytoskeleton 
is desmoplakin (DP), a requisite mediator of mechanical strength 
in skin and heart. The importance of DP is underscored by the 
failure of DP-null murine embryos to survive beyond embryonic 
day 6.5 (E6.5) because of destabilization of desmosomes leading 
to egg cylinder elongation defects (Gallicano et al., 1998). Tetra-
ploid analysis and tissue-specific conditional knockouts (KOs) 
later demonstrated a requirement for DP in vascular develop-
ment, epidermal integrity, and cardiac function (Gallicano et 
al., 2001; Vasioukhin et al., 2001; Lyon et al., 2014). In the case 
of heart, conditional DP KO recapitulated the pathology of the 
human cardiac disease arrhythmogenic cardiomyopathy (ACM), 
which has been associated with mutations in desmosomal com-
ponents (Asimaki and Saffitz, 2014; Lyon et al., 2014). Pathogenic 
DP mutations are the second most frequently identified in ACM 
and can be present either with or without cutaneous phenotypes 
(Alcalai et al., 2003; López-Ayala et al., 2014; Molho-Pessach et al., 
2015; Castelletti et al., 2017). In ACM, healthy myocardium is pro-
gressively replaced with fibrofatty tissue deposits that can ulti-
mately lead to ventricular arrhythmias and sudden cardiac death 
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(Basso et al., 1996, 2009; Sen-Chowdhry et al., 2007). Although 
best known for their roles in intercellular adhesion, desmosome 
components have emerged as regulators of intracellular signal-
ing (Bass-Zubek et al., 2008; Godsel et al., 2010; Wolf et al., 2013; 
Rötzer et al., 2016). DP in particular has been implicated in the 
regulation of signaling pathways involved in the adipogenic and 
fibrogenic aspects of ACM pathogenesis (Garcia-Gras et al., 2006; 
Dubash et al., 2016; Lombardi et al., 2016). However, the molecu-
lar mechanisms by which desmosomal mutations lead to disease 
pathogenesis are not well understood.
While desmosomal and adherens junctions components 
of the ID facilitate mechanical coupling between neighboring 
cardiomyocytes, evidence suggests that they are physically and 
functionally integrated with gap junctions and sodium chan-
nels to facilitate electrical conduction at these nodes (Saez et al., 
2003; Laird, 2006; Goodenough and Paul, 2009; Stroemlund et 
al., 2015). Vertebrate gap junctions are made up of proteins from 
the 21-gene connexin family, whereby hexamers of connexin 
proteins (termed connexons) formed on two adjacent cells dock 
with each other to produce channels that allow for the passage 
of small molecules and ions (Laird, 2006; Goodenough and Paul, 
2009). Of these members, connexin-43 (Cx43) is the most ubiq-
uitously expressed connexin in many tissues and cultured cells 
(Laird, 2006). We previously showed that DP plays an important 
role in the delivery of Cx43 to the plasma membrane via an EB1–
microtubule-dependent pathway (Patel et al., 2014). In addition, 
two independent mouse models with cardiac conditional DP KO 
(DPcKO) reported that DP loss also leads to a significant reduc-
tion in Cx43 protein levels (Gomes et al., 2012; Lyon et al., 2014). 
The loss of Cx43 expression in these models was speculated to 
contribute to a feature of ACM called the “concealed phase,” 
in which electrical conduction defects occur before fibrofatty 
replacement of healthy myocardium (Saffitz et al., 2010; Gomes 
et al., 2012; Lyon et al., 2014). However, the molecular mecha-
nism by which loss of DP leads to a decrease in Cx43 is unknown. 
Given the unique organization of cardiac cell junctions, cardio-
myocytes provide an ideal model for studying the structural 
and functional dynamics of intercellular junctions and how 
interfering with normal integration of intercellular junctions 
leads to disease (Garcia-Gras et al., 2006; Cerrone et al., 2012; 
Lyon et al., 2014).
In this study, we characterize a novel mechanism by which 
DP loss leads to Cx43 protein degradation. Depletion of DP trig-
gers robust activation of the ERK1/2–MAPK pathway, resulting 
in phosphorylation of residues S279 and 282 within the intra-
cellular C terminus of Cx43. These consensus ERK1/2 phosphor-
ylation sites are known to be phosphorylated in tandem to mark 
Cx43 for degradation (Fong et al., 2014). We further show that 
DP loss elevates mRNA, protein, and activity of the canonical 
upstream activator of ERK1/2, K-Ras, in cardiac cells but not in 
an epidermal model of DP loss. Inhibition of Ras using either 
K-Ras knockdown (KD) or a novel peptide inhibitor derived 
from a toxin secreted by the bacterium Vibrio vulnificus res-
cued Cx43 expression and localization caused by DP loss. Along 
with our previous work (Patel et al., 2014), these data support 
the idea that loss of DP interferes with both transcriptional and 
posttranslational mechanisms controlling Cx43 expression and 
localization and provide a new perspective on the molecular 
events leading to cardiac arrhythmias and other connexin-based 
disorders in skin and heart.
Results
DP loss impairs the expression and localization of the gap 
junction protein Cx43
Previous studies showed that DP loss is associated with decreased 
expression of Cx43 in cardiac tissue (Gomes et al., 2012; Lyon et 
al., 2014). Toward determining the mechanism by which DP reg-
ulates Cx43 protein levels, we used cultured neonatal rat ven-
tricular cardiomyocytes (NRV CMs) and the HL-1 mouse atrial 
cardiomyocyte line (Claycomb et al., 1998). Previous in vitro anal-
yses comparing primary cardiomyocytes and HL-1 cells with in 
vivo models of cardiac disease demonstrated the utility of these 
cell culture models for defining molecular mechanisms under-
lying desmosome-related cardiac disorders (Garcia-Gras et al., 
2006; Cerrone et al., 2012, 2014; Lyon et al., 2014).
To verify the dependence of Cx43 protein levels on the pres-
ence of DP in vitro, freshly isolated NRV CMs were treated with 
an adenovirus harboring either control (nontargeting) or DP KD 
shRNA constructs, and HL-1 cells were transfected with either 
control or DP KD–specific siRNA. In both cardiac cell types, 
depletion of DP resulted in a substantial decrease in Cx43 pro-
tein levels, consistent with that observed in a cardiac restricted 
mouse model harboring DP deletion (Fig. 1, A and A′; Lyon et al., 
2014). Furthermore, the fluorescence intensity of Cx43 staining 
at cell–cell junctions was substantially reduced in DP KD car-
diomyocytes compared with controls (Fig. 1, B and B′). DP loss 
did not detectably alter the expression or distribution of other 
cardiac junctional components whose disruption might have 
contributed to the observed decrease in Cx43, including plako-
globin (Pg), N-cadherin, and α-catenin (Fig. 1, C and D). Although 
DP KD resulted in a small decrease in plakophilin 2 (PKP2) lev-
els (Fig. 1 C), we previously showed that DP can restore defects 
resulting from PKP2 loss (Dubash et al., 2016).
To test whether the loss of DP is responsible for the observed 
decrease in Cx43 protein levels, we assessed whether expres-
sion of exogenous DP was sufficient to recover Cx43 expression. 
To achieve this, DPII-GFP was delivered using an adenovirus in 
the background of DP KD. DPII is a naturally occurring isoform 
of DPI that is lacking in the rod domain (6.8 vs. 8.6 kb). This 
construct was used to overcome technical limits in size for ade-
noviral packaging and transduction. Like DPI, DPII is localized 
to desmosomes and confers adhesive strength to cell–cell junc-
tions (Angst et al., 1990; Green et al., 1990; Cabral et al., 2012; 
Patel and Green, 2014). Expression of full-length DPII was suf-
ficient to restore Cx43 localization to cell junctions as assessed 
by immunofluorescence (Fig.  1, E and E′). Additionally, DPII 
expression restored Cx43 protein to control levels in the back-
ground of DP KD as assessed by Western blot (Fig. 1, F and F′). 
Collectively, these data demonstrate that DP is essential for the 
stable expression of Cx43 protein and its incorporation into gap 
junctions in cardiac cells.
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DP loss results in elevated phosphorylation of Cx43 at MAPK-
regulated S279/282 sites
Connexins exhibit short half-lives on the order of 1–5 h compared 
with other membrane proteins, which typically exhibit half-lives 
on the order of 24–48 h (Laird et al., 1991; Beardslee et al., 1998). 
Gap junctions are therefore highly dynamic structures that are 
constantly undergoing assembly, remodeling, and turnover 
(Solan and Lampe, 2014). Posttranslational modification of Cx43, 
particularly phosphorylation, has been extensively studied as a 
mechanism by which gap junction dynamics are regulated. Of 
the 26 serines in the intracellular serine-rich C-terminal region 
of Cx43, at least 19, along with two of six tyrosines, have been 
identified as phosphorylation sites (Axelsen et al., 2013). Given 
the importance of phosphorylation for the connexin life cycle, we 
asked whether DP plays a role in modulating Cx43 phosphoryla-
tion. To address this question, control and DP KD NRV CMs were 
tested with phosphosite-specific Cx43 antibodies (Márquez-
Rosado et al., 2012). Interestingly, an increase in phosphoryla-
tion of a linked pair of Cx43 sites at S279/282 was detected in 
response to DP KD (Fig. 2 A). Phosphorylation at this pair has 
been implicated in down-regulation of gap junction intercellu-
lar communication as well as internalization and degradation of 
Cx43 (Norris et al., 2008; Johnson et al., 2013; Fong et al., 2014). 
When normalized to total Cx43 protein levels that are reduced 
in the absence of DP, the ratio of p-Cx43 S279/282 to total Cx43 
increased approximately fourfold in DP KD NRV CMs (Fig. 2 A′).
As phosphorylation at Cx43 S279/282 sites is mediated by 
ERK1/2, we tested whether depletion of DP affects activation of 
the ERK1/2–MAPK pathway (Warn-Cramer et al., 1996). Indeed, 
by Western blot, robust activation of p-ERK1/2 levels was observed 
in response to DP KD in NRV CMs (Fig. 2, B and B′). The original 
observation that DP loss leads to reduced Cx43 protein expression 
was made in a cardiac conditional KO mouse model (Lyon et al., 
2014). To test whether DP loss leads to increased p-Cx43 S279/282 
in cardiac tissue, immunofluorescence analysis was performed on 
cardiac sections from the aforementioned DPcKO mouse. Cx43 
staining intensity at the IDs of DPcKO heart sections was signifi-
cantly decreased compared with WT (Fig. 2, C and C′). However, 
DPcKO cardiac sections display elevated levels of p-Cx43 S279/282 
staining compared with WT (Fig. 2 C). Quantification of p-Cx43 
S279/282 normalized to total Cx43 at IDs (as marked by Pg stain-
ing) revealed an approximately fourfold increase in the p-Cx43/
total Cx43 ratio in DPcKO versus WT hearts (Fig. 2 C″).
To determine whether the observed loss of Cx43 was asso-
ciated with a functional loss of gap junction intercellular 
communication (GJIC), scrape loading dye transfer assays were 
performed. HL-1 cells grown to a confluent monolayer were 
scraped and treated with the gap junction permeable dye Lucifer 
Yellow (LY). GJIC was evaluated by the number of cells display-
ing positive LY signal, indicative of level of dye transfer between 
neighboring cells. DP depletion resulted in a significant reduc-
tion in LY signal transferred between cells compared with control 
(Fig. 2, D and D′). Furthermore, reexpression of full-length DPII 
restored levels of dye transfer to that of control cells (Fig. 2, D and 
D′). These data demonstrate that the decreased expression and 
assembly of Cx43 into gap junctions caused by DP loss perturbs 
gap junction function.
Cx43 phosphorylation is altered in ACM
To determine whether this pathway has relevance in ACM, a 
blinded experiment was performed using cardiac sections from 
healthy controls or ACM patients harboring pathogenic muta-
tions in DP or PKP2. All patient samples discussed in this section 
are unpublished. Immunofluorescence analysis of total Cx43 
and p-Cx43 S279/282 was assessed, and in parallel, DP staining 
was performed to evaluate the consequence of the mutations to 
DP’s localization at IDs. Healthy control tissue displayed strong 
total Cx43 signal at IDs (Fig. 3 B and S1 A). Additionally, control 
sections did not show appreciable ID or cytoplasmic p-Cx43 
S279/282 signal (Fig. 3 B). In contrast, cardiac tissue from two 
of the ACM patients harboring mutations in DP at 1,218+1 G→A 
and C3337T, respectively, displayed almost complete loss of total 
Cx43. The only detectable signal was nonspecific lipofuscin aut-
ofluorescence (Fig. S1 A, white arrowheads). These data are con-
sistent with the reported loss of Cx43 from IDs of both DP ACM 
and Carvajal syndrome (cardiocutaneous syndrome caused by DP 
mutations) patients (Kaplan et al., 2004; Asimaki et al., 2009; 
Gomes et al., 2012). Assessment of p-Cx43 S279/282 could not be 
performed in these patients as we could not detect appreciable 
total Cx43 signal. Both patients also showed severe impairment 
of DP localization to IDs as marked by Pg staining compared with 
healthy controls (Fig. S1, B and B′).
In contrast, analysis of DP ID localization in cardiac tis-
sue from an ACM patient harboring a pathogenic mutation in 
PKP2 at 971_980del10 showed significantly impaired (Fig. 3 A, 
white arrowheads) but not complete loss of DP from IDs com-
pared with control (Fig. 3 A [inset] and Fig. 3 A′). The loss of DP 
resulting from a PKP2 mutation is consistent with our previ-
ous work showing that PKP2 loss in cardiac cells promotes the 
destabilization of DP protein and its subsequent degradation 
Figure 1. DP KD results in decreased levels of Cx43 in cardiac cells. (A) NRV CMs and HL-1 cells were treated with DP-specific shRNA and siRNA, respec-
tively, and samples were analyzed 72 h after infection/transfection. DP KD leads to a significant reduction of Cx43 protein levels in both cell types (HL-1, n = 4; 
NRV CM, n = 6. (A′) Densitometry quantification of Cx43 levels normalized to loading control. (B) Control (CT) and DP KD NRV CMs grown on glass coverslips and 
stained for Cx43. DP KD results in a decrease of Cx43 junctional localization (n = 5). (B′) Quantification of Cx43 membrane intensity (normalized to junctional 
Pg signal) in control and DP KD NRV CMs. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by two tailed Student’s t test. (C) Control and DP KD NRV CMs were 
blotted for the following cardiac junctional components: DP, PKP2, Pg, N-cadherin, and α-catenin (n = 3). Densitometry quantification is representative of three 
independent experiments. (D) Control and DP KD NRV CMs were seeded on glass coverslips and stained for PKP2, Pg, N-cadherin, α-catenin, and β-catenin (n 
= 3). (E and E′) Re-expression of full-length human DPII rescues Cx43 junctional localization in NRV CMs (n = 3). Quantification of junctional Cx43 (normalized 
to Pg) shows that DPII expression causes a significant restoration of Cx43 membrane localization. Bars, 20 µm. (F) Re-expression of DPII restores Cx43 protein 
levels in NRV CMs by Western blot (n = 3). (F′) Densitometry quantification of Cx43 levels normalized to loading control. Error bars represent mean ± SD. **, P 
< 0.01; ***, P < 0.001; ****, P < 0.0001 by one-way ANO VA followed by Tukey’s post hoc test.
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via the proteasome (Dubash et al., 2016). Furthermore, this 
patient displayed significantly lowered Cx43 ID staining com-
pared with control without complete loss of expression (Fig. 3, 
B and B′). This patient’s cardiac tissue showed an approximately 
threefold increase in p-Cx43 S279/282 to total Cx43 (Fig. 3 B″), 
reminiscent of elevated p-Cx43 S279/282 signal seen in DPcKO 
murine hearts (Fig. 2 C). The milder Cx43 phenotype observed 
in this ACM patient compared with those harboring patho-
genic DP mutations may have resulted from the presence of 
residual DP at IDs.
Figure 2. Loss of DP leads to elevated phos-
phorylation of Cx43 at S279/282 in cardiac 
models. (A) NRV CMs treated with control and 
DP KD shRNA were blotted for total Cx43 and 
p-Cx43 S279/282 72  h after infection (n = 3). 
(A′) Densitometry was performed to quantify 
the ratio of p-Cx43 S279/282 to total Cx43 lev-
els. (B) Control and DP KD NRV CMs were blot-
ted for p-ERK1/2 levels, revealing an increase in 
p-ERK1/2 levels in DP KD compared with con-
trol (n = 4). (B′) Densitometry quantification of 
p-ERK1/2 levels normalized to loading controls. 
(C) WT and DPcKO heart sections were stained 
for total Cx43, p-Cx43 S279/282, and Pg (n = 3). 
Boxed regions in color overlays are magnified 
in the panels on the right. Bars: 20 µm (main 
images); 10 µm (insets). (C′) Quantification of 
total Cx43 localized at IDs (normalized to Pg). 
(C″) Quantification of the p-Cx43 S279/282 to 
total Cx43 ratio localized at IDs. *, P < 0.05; **, P 
< 0.01; ****, P < 0.0001 by two-tailed Student’s 
t test. (D and D′) Scrape loading dye transfer 
assays were performed on CT KD, DP KD, and 
DP KD HL-1 cells expressing full-length DPII. The 
total number of cells displaying LY dye transfer 
was quantified (n = 3). Bar, 100 µm. Error bars 
represent mean ± SD. **, P < 0.01 by one-way 
ANO VA followed by Tukey’s post hoc test.
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Elevated phosphorylation of Cx43 at S279/282 is conserved in 
an epidermal restricted DP mouse KO model
In addition to cardiocutaneous disorders such as Carvajal syn-
drome, dominant de novo DP mutations have recently been 
reported to cause erythrokeratodermia–cardiomyopathy syn-
drome associated with impaired Cx43 membrane localization in 
the skin (Boyden et al., 2016). Thus, we next addressed whether 
DP regulates Cx43 levels in the epidermis, where it plays a vital 
role in epidermal proliferation and differentiation (Norgett et 
al., 2000; Langlois et al., 2007, 2010), using an epidermal condi-
tional KO mouse model of DP (DPeKO; Vasioukhin et al., 2001). 
Immunofluorescence analysis demonstrated that the previously 
reported abnormal morphology in DPeKO epidermis was accom-
panied by significantly lower Cx43 membrane staining (Fig. 4, 
Figure 3. Increased phosphorylation of Cx43 
at S279/282 is conserved in a PKP2 ACM 
patient sample. (A and A′) Healthy control and 
PKP2 ACM (971_980del10) human cardiac sec-
tions were stained for DP and Pg as a marker of 
IDs (n = 1). DP ID localization was quantified (nor-
malized to Pg ID intensity). Boxed regions in color 
overlays are magnified in the panels on the right 
showing regions with retained DP ID localization. 
White arrows denote IDs showing positive Pg 
staining without presence of DP. (B) Control and 
PKP2 ACM cardiac sections were stained for total 
Cx43, p-Cx43 S279/282, and Pg (n = 1). Bars: 20 
µm (main images); 10 µm (insets). (B′) Quantifi-
cation of total Cx43 localized at IDs normalized 
to Pg. (B″) Quantification of the p-Cx43 S279/282 
to total Cx43 ratio at IDs normalized to Pg. Error 
bars represent mean ± SD. ****, P < 0.0001 by 
two-tailed Student’s t test.
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A and A′; Vasioukhin et al., 2001). We also observed an increase 
in p-Cx43 S279/282 levels in DPeKO samples compared with WT 
by Western blot (Fig.  4  B) and immunofluorescence (Fig.  4, C 
and C′), paralleling what was observed in cardiac cells. Further-
more, the ratio of p-Cx43 S279/282 to total Cx43 levels revealed 
an approximately twofold increase in DPeKO samples compared 
with WT (Fig. 4 B′). Accompanying the observed changes in Cx43, 
p-ERK1/2 levels increased in DPeKO epidermis compared with 
WT (Fig. 4 B). Collectively, these data suggest that DP-dependent 
regulation of Cx43 phosphorylation at the p-ERK1/2–MAPK-spe-
cific residues, S279/282, is a conserved mechanism in cardiac and 
cutaneous models.
DP loss leads to elevated ubiquitination and 
degradation of Cx43
Phosphorylation of Cx43 at S279/282 has been shown to trig-
ger internalization and degradation of Cx43 (Fong et al., 2014). 
To test whether depletion of DP leads to degradation of Cx43 in 
cardiac cells, Cx43 protein stability was analyzed in response 
to DP KD by treating HL-1 cells with cycloheximide for the indi-
cated times. Cx43 protein degraded at a higher rate in DP KD 
cells compared with control (Fig. 5, A and A′). Quantitative PCR 
(qPCR) analysis showed that DP KD did not have a significant 
effect on Cx43 transcript levels in NRV CMs, suggesting that 
DP-dependent regulation of Cx43 expression does not occur 
at the mRNA level (Fig. S2). Degradation of Cx43 has been 
shown to occur via either the proteasomal or lysosomal path-
ways depending on cell type and degradation stimulus (Laing 
et al., 1997; Leithe and Rivedal, 2004; Leithe et al., 2006). To 
identify the machinery responsible for Cx43 degradation in 
response to DP loss, we used the proteasomal inhibitor MG132 
or the lysosomal inhibitor chloroquine in the background of 
DP KD. Surprisingly, MG132 treatment resulted in a decrease 
in Cx43 expression in control cells without decreasing DP lev-
els (Fig. 5 B). MG132 treatment further decreased the levels 
of Cx43 observed upon DP KD (Fig. 5 B). In contrast, chloro-
quine treatment caused an accumulation Cx43 protein levels 
in control cells and restored Cx43 expression in DP KD cells. 
These data are consistent with lysosomal-mediated degrada-
tion of Cx43 at steady state, which is exacerbated by loss of 
DP (Fig. 5 C).
Cx43 is modified by ubiquitination, a tag that is thought 
to target the connexin for subsequent degradation (Laing and 
Beyer, 1995; Leithe and Rivedal, 2004; Chen et al., 2012). To 
Figure 4. Elevated Cx43 phosphorylation 
at S279/282 is conserved in an epidermal 
restricted model of DP loss. (A and A′) WT 
and DPeKO epidermal sections were stained 
for Cx43 and Pg. DPeKO sections display signifi-
cantly lowered Cx43 membrane intensity (n = 
3). (B) Western blot analysis performed on WT 
and DPeKO lysates show decreased total Cx43 
and increases in p-ERK1/2 and p-Cx43 S279/282 
levels in DPeKO compared with WT (n = 3). (B′) 
Densitometry was performed to quantify the 
ratio of p-Cx43 S279/282 to total Cx43 levels. (C 
and C′) WT and DPeKO epidermis were stained 
for p-Cx43 S279/282 and Pg. DPeKO show signifi-
cantly higher levels of p-Cx43 S279/282 staining 
intensity (n = 3). Bars, 20 µm. Error bars repre-
sent mean ± SD. **, P < 0.01; ****, P < 0.0001 by 
two-tailed Student’s t test.
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determine whether Cx43 is ubiquitinated in response to DP loss, 
immunoprecipitates of endogenous Cx43 from control and DP 
KD NRV CMs were immunoblotted for endogenous ubiquitin. 
Using the mono/polyubiquitin antibody FK2, it was observed 
that Cx43 is more highly ubiquitinated in DP KD samples com-
pared with control (Fig. 5 D). To determine whether increased 
ubiquitination of Cx43 is conserved in mouse epidermis lacking 
DP, proximity ligation assay (PLA) was used to detect ubiquitin 
modification of Cx43 in mouse tissue sections. PLA allows for 
the in situ visualization of two antigens that are in close prox-
imity to each other (40–100 nm). This assay is used frequently 
to detect posttranslational modifications on target proteins 
(Fredriksson et al., 2002; Söderberg et al., 2006; Ristic et al., 
2016). DPeKO epidermis produced significantly more Cx43-Ub 
PLA signal compared with WT, suggesting that DP-dependent 
ubiquitination of Cx43 is conserved in the heart and skin 
(Fig. 5, E and E′).
Blockade of Cx43 phosphorylation is sufficient to rescue Cx43 
expression and localization
Our data suggest that DP loss activates p-ERK1/2–MAPK, which 
in turn phosphorylates Cx43 on S279/282 to target Cx43 for 
degradation. To directly test whether preventing Cx43 phos-
phorylation blocks degradation and restores junctional local-
ization of Cx43, DP KD NRV CMs were treated with U0126, a 
small-molecule inhibitor of MEK1/2, the direct upstream 
activators of p-ERK1/2. U0126 treatment restored p-ERK1/2 
and total Cx43 expression levels to those of control (Fig. 6 A). 
Additionally, when normalized to total Cx43 levels, the p-Cx43 
S279/282 signal was also restored to a level comparable with 
control (Fig. 6 A′).
Immunofluorescence analysis using Pg as a marker of cell 
junctions revealed that U0126 treatment also partially restores 
localization of Cx43 to cell junctions (Fig. 6, B and B′). The differ-
ence in restoration between protein levels and localization may 
Figure 5. Loss of DP promotes ubiquitination and degradation of Cx43. (A) Control and DP KD HL-1 cells were treated with cycloheximide for the indicated 
time points, and samples were blotted for DP and Cx43 (n = 4). (A′) Densitometry quantification was performed to assess rate of Cx43 degradation. (B) MG132 
was used to assess role of proteasomal degradation of Cx43 caused by DP loss in NRV CMs (n = 3). (C) The lysosomal inhibitor Chloroquine was able to restore 
Cx43 expression levels in response to DP KD in NRV CMs (n = 3). (D) Cx43 was immunoprecipitated from control and DP KD NRV CMs. Samples were subse-
quently blotted for Cx43 and ubiquitin. Whole-cell lysate (WCL) from these samples is to the right (n = 4). (E and E′) WT and DPeKO epidermal sections were 
subjected to PLA analysis with Cx43 and ubiquitin antibody pairs (n = 3). Bar, 20 µm. Quantification of PLA dots normalized to DAPI count revealed a significant 
increase in Cx43-Ubiquitin PLA in DPeKO compared with WT skin. Error bars represent mean ± SD. **, P < 0.01; ***, P < 0.001 by two-tailed Student’s t test.
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be explained by our previous demonstration that DP also func-
tions posttranslationally to promote the delivery of Cx43 to cell 
junctions via microtubules (MTs) in keratinocytes via an asso-
ciation with MT plus end protein EB1 (Patel et al., 2014). These 
data suggest that blocking the initial phosphorylation of Cx43 by 
p-ERK1/2 is sufficient to prevent Cx43 loss in DP-deficient condi-
tions and to help restore membrane localization of Cx43, where 
it can be assembled into gap junction complexes.
DP inhibits the ERK–MAPK pathway via suppression of RAS
Toward identifying candidate mechanisms by which DP loss 
activates the ERK1/2–MAPK pathway, we compared control and 
DPKD NRV CMs using large-scale unbiased RNA sequencing 
(RNA-seq) analysis. Notably, levels of V-Ki-ras2 Kirsten rat sar-
coma viral oncogene homologue (KRAS) RNA were significantly 
up-regulated in DP KD samples. K-Ras as is one of the three major 
isoforms of the Ras GTPase family, which include H-Ras and 
N-Ras (Castellano and Santos, 2011; Hobbs et al., 2016). Mutations 
in these proteins frequently lead to malignancies, with gain-of-
function missense mutations in RAS genes having been found in 
∼25% of human cancers (Hobbs et al., 2016). Ras is well known 
to initiate a signaling cascade involving the subsequent activa-
tion of the Raf–MEK–ERK pathway (Roberts and Der, 2007). To 
validate DP’s regulation of Ras transcript levels, qPCR analysis of 
the three major Ras isoforms (KRAS, HRAS, and NRAS) was com-
pared in control and DP KD NRV CMs. Depletion of DP resulted in 
significant increases of K-Ras and H-Ras transcript levels but not 
of N-Ras (Fig. 7 A).
Because the KRAS transcript displayed the most substantial 
increase (sevenfold), we assessed K-Ras protein levels in response 
to DP KD. Western blot analysis showed that K-Ras protein expres-
sion is elevated in DP KD cells compared with control (Fig. 7, B 
and B′). The protein kinase c-Raf directly binds to GTP-loaded 
Ras proteins to propagate the MAPK pathway via the subsequent 
phosphorylation and activation of MEK, the kinase that in turn 
phosphorylates and activates ERK1/2 (Roberts and Der, 2007). 
As such, we exploited PLA to measure Ras–Raf interactions as 
an indicator of elevated Ras activation in vivo under DP KO con-
ditions. K-Ras/c-Raf PLA signal was significantly increased in 
DPcKO hearts compared with WT, affirming that DP-dependent 
Ras activation is conserved in vivo (Fig. 7, C and C′).
Toward determining whether K-Ras is responsible for DP-de-
pendent activation of the ERK1/2–MAPK pathway, we used a 
recently described bacterial toxin-derived Ras/Rap1-specific 
peptidase (RRSP; Antic et al., 2015). RRSP’s ability to inhibit 
Ras activity in mammalian cells is notable as Ras proteins have 
been notoriously difficult to target pharmacologically (Cox et al., 
2014). RRSP is derived from DUF5Vv (domain of unknown func-
tion in fifth position), a naturally occurring effector domain from 
the multifunctional-autoprocessing-repeats-in-toxins (MAR TX) 
toxin of the bacterium V. vulnificus (Antic et al., 2015; Biancucci 
et al., 2017). This protein represents a new class of endopeptidase 
that specifically processes all three major Ras isoforms as well as 
Rap1, blunting their activity and downstream activation of the 
ERK1/2–MAPK pathway, and which has so far been tested solely 
on cancer cell lines in an in vitro setting (Antic et al., 2015).
RRSP was functionalized for delivery into cells by fusion of 
the DUF5Vv domain to the N terminus of anthrax toxin lethal fac-
tor (LFNDUF5Vv), followed by introduction of the fusion protein 
to NRV CMs using anthrax toxin protective agent (PA; Antic et al., 
2015). RRSP effectively reduced p-ERK1/2 levels in NRV CMs, con-
sistent with dampened Ras activation (Fig. S3). Having validated 
RRSP efficacy in cardiomyocytes, we next tested whether RRSP 
would be able to rescue DP-dependent Ras activation. We used 
a Ras-GTP antibody that specifically recognizes Ras in its GTP-
bound active state. Immunofluorescence analysis revealed that 
Figure 6. Blockade of p-ERK1/2–MAPK activation is sufficient to rescue 
Cx43 expression and localization. (A) Control, DP KD, and DP KD NRV CMs 
treated with 5 µM U0126 or vehicle were blotted for DP, p-ERK1/2, Cx43, 
and p-Cx43 S279/282 (n = 4). (A′) Densitometry quantification shows that 
U0126 treatment was sufficient to significantly restore the p-Cx43 S279/282 
to total Cx43 ratio to control levels. (B) Immunofluorescence analysis of 
NRV CMs treated with control or DP KD shRNA in the presence or absence 
of 5 µM U0126 stained for Cx43 and Pg (n = 3). Bar, 20 µm. (B′) Quantifica-
tion of Cx43 junctional localization normalized to junctional Pg. U0126 treat-
ment led to significant restoration of junctional Cx43. Error bars represent 
mean ± SD. **, P < 0.01; ****, P < 0.0001 by one-way ANO VA followed by 
Tukey’s post hoc test.
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DP KD resulted in a significant up-regulation of Ras-GTP signal, 
which was restored to control levels with RRSP treatment (Fig. 7, 
D and D′). RRSP treatment also efficiently inhibited p-ERK1/2 
activation that occurred in response to DP KD (Fig. 7 E).
To confirm that RRSP suppresses p-ERK by inhibiting K-Ras, 
we generated shRNA specific to K-Ras and showed that it is capa-
ble of knocking down K-Ras along with a concurrent decrease 
in p-ERK1/2 in NRV CMs (Fig. 7 F). We next performed a double 
KD of K-Ras and DP and showed that silencing of K-Ras reduced 
p-ERK1/2 back to control levels in DP-deficient NRV CMs, indicat-
ing that DP-dependent activation of the ERK1/2–MAPK pathway 
is caused by elevated K-Ras signaling (Fig. 7 G). As robust acti-
vation of ERK1/2–MAPK signaling was observed in an epider-
mal model of DP deletion (Fig. 4 B), we addressed whether DP’s 
effects on Ras expression are conserved in the skin. qPCR analy-
sis revealed that transcript levels of all three major Ras isoforms 
are not significantly changed in DPeKO epidermis compared 
with WT (Fig. S4). This finding is consistent with the idea that 
ERK1/2–MAPK activation depends on factors other than modu-
lation of Ras mRNA levels in DPeKO epidermis.
To determine whether ERK-dependent reduction of Cx43 
depends on K-Ras in DP-deficient cells, we assessed Cx43 levels in 
RRSP-treated or K-Ras KD NRV CMs. Both RRSP and K-Ras shRNA 
restored total Cx43 as well as the ratio of p-Cx43 S279/282 to that 
of control samples (Fig. 7, E, E′, G, and G′). Similar to U0126 treat-
ment, RRSP also significantly restored Cx43 localization to cell 
junctions in NRV CMs in DP KD cells (Fig. 7, H and H′). Finally, 
DPII expression in the background of DP KD was sufficient to 
restore K-Ras, p-ERK1/2, and the ratio of p-Cx43 S279/282 to total 
Cx43 levels to that of control (Fig. 7, I and I′).
Discussion
This work reveals a novel mechanism by which DP keeps Ras in 
check to stabilize Cx43 in the gap junctions of cardiomyocytes. 
Upon loss of DP either in vitro or in vivo, ERK1/2–MAPK signaling 
is activated, resulting in phosphorylation of Cx43 at S279/282, an 
event that signals Cx43 for degradation that is performed via the 
lysosome (Fig. 8). This finding provides new insight into the role 
of DP in the maintenance of gap junction stability and provides 
a potential explanation for the previously observed decrease in 
Cx43 expression identified in a mouse model of ACM (Lyon et al., 
2014). In these mice, diminished Cx43 was associated with car-
diac electrical conduction defects before fibrofatty replacement 
of the myocardium, similar to the concealed phase of ACM 
(Asimaki and Saffitz, 2012; Lyon et al., 2014). Our data provide 
a potential explanation for how DP loss could contribute to the 
concealed phase through regulation of Cx43 protein levels via 
modulation of Cx43 posttranslational modifications.
We identified Ras as a key link between DP and Cx43 regulation. 
Inhibition of Ras activity using a novel Ras inhibitor, RRSP, or by 
silencing with shRNA targeting K-Ras, demonstrated that ERK1/2 
activation and associated loss of Cx43 expression was mediated by 
increased Ras expression and activity in DP-deficient cells. How 
DP regulates Ras mRNA levels is not yet understood. Although 
regulatory mechanisms controlling Ras transcription are not well 
characterized, one possibility is that loss of DP enhances the rate 
of Ras gene transcription via activation of transcription factors/
cofactors. DP-dependent regulation of Ras transcript levels could 
also be through epigenetic mechanisms, for instance via the action 
of specific microRNAs that have been shown to be responsible for 
controlling Ras expression levels in various cell types (Shin et al., 
2011; Wang et al., 2014; Zhang et al., 2014). To date, there have 
been no pharmacological inhibitors of Ras that have made it to 
the clinic despite massive efforts to target this pathway given its 
prevalence in human cancers, prompting the assertion that Ras 
proteins are “undruggable” (Baines et al., 2011; Cox et al., 2014). In 
addition to its ability to process all three major Ras isoforms, RRSP 
has also been shown to be effective toward the inhibition of vari-
ous mutant forms of K-ras that are widely associated with human 
cancers (Antic et al., 2015). Our work provides additional evidence 
that RRSP is an effective inhibitor of Ras and establishes a potential 
use of this novel reagent for clinical purposes.
We also show that DP loss leads to activation of the ERK1/2–
MAPK pathway in epidermal and cardiac models of DP deficiency. 
It is well established that elevated ERK1/2–MAPK signaling in the 
heart results in cardiac hypertrophy, an abnormal enlargement 
of the heart caused by increased cardiomyocyte size (Wang, 2007; 
Lorenz et al., 2009). Thus, it is plausible that abnormal ERK1/2 
signaling could contribute to disease pathogenesis including car-
diomyocyte hypertrophy in cardiac patients harboring mutations 
in DP (or factors that regulate its expression or localization). In 
epithelial cells, both activation of ERK1/2 signaling and loss or 
impairment of DP can lead to altered proliferation, migration, 
and differentiation (Matsubayashi et al., 2004; Setzer et al., 2004; 
Khavari and Rinn, 2007; Yang et al., 2012). That depletion of DP 
in the HaCaT keratinocyte cell line resulted in increased prolifer-
ation associated with elevated p-ERK1/2 levels is consistent with 
Figure 7. DP modulates the ERK1/2–MAPK pathway via regulation of Ras expression. (A) Control and DP KD NRV CMs were analyzed for mRNA levels of 
KRAS, HRAS, and NRAS (n = 3). (B) NRV CMs treated with control and DP KD shRNA were blotted with a K-Ras antibody (n = 3). (B′) Densitometry quantification 
of K-ras levels normalized to loading controls. (C and C′) WT and DPcKO cardiac sections were subjected to PLA analysis with K-Ras/c-Raf antibody pairs (n = 
3). Quantification of PLA signal normalized to DAPI count shows that K-Ras/c-Raf PLA signal is significantly increased in DPcKO compared with WT hearts. *, 
P < 0.05; **, P < 0.01 by two-tailed Student’s t test. (D) Immunofluorescence analysis of Ras-GTP staining was performed on control, DP KD, and DP KD NRV 
CMs treated with 2 nM RRSP (n = 3). (D′) Quantification of Ras GTP staining intensity. (E) CT KD and DP KD were compared with CT KD and DP KD NRV CMs 
treated with 2 nM RRSP by blotting for DP, p-ERK1/2, p-Cx43 S279/282, and Cx43 (n = 3). (E′) Densitometry quantification of p-Cx43 S279/282 to total Cx43 
ratio. (F) Control and K-Ras KD NRV CMs were blotted for DP, p-ERK1/2, and K-Ras protein levels (n = 3). (G and G′) Control, DP KD, and DP/K-Ras double KD 
NRV CMs were subjected to Western blot analysis for DP, p-ERK1/2, Cx43, p-Cx43 S279/282, and K-Ras levels (n = 3). The ratio of Cx43 to p-Cx43 S279/282 
was quantified by densitometry. (H) Control, DP KD, and DP KD NRV CMs treated with 2 nM RRSP were stained for Cx43 and Pg as a marker of cell junctions (n 
= 3). (H′) Quantification of Cx43 junctional intensity normalized to junctional Pg. Bars, 20 µm. (I and I′) Control, DP KD, and DP KD NRV CMs expressing DPII 
were blotted for DP, Cx43, p-Cx43 S279/282, and K-Ras. The ratio of Cx43 to p-Cx43 S279/282 was quantified by densitometry. Error bars represent mean ± 
SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by one-way ANO VA followed by Tukey’s post hoc test.
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the possibility that DP-dependent regulation of cell behavior is 
mediated at least in part through its ability to attenuate ERK activ-
ity (Wan et al., 2007).
In this work, we use a previously published mouse model 
harboring cardiomyocyte specific conditional KO of DP using 
ventricular myosin light chain-2–Cre mice that recapitulates 
the pathological progression of ACM (Lyon et al., 2014). The 
authors observed wavefront propagation defects that were 
associated with loss of Cx43 expression. Our data suggest that 
DP loss triggers activation of the ERK1/2–MAPK pathway that 
then signals Cx43 for subsequent degradation by phosphory-
lation of the putative MAPK sites, S279/282. A conditional KO 
model whereby DP was deleted from the sinoatrial node (SAN) 
using the Hcn4-Cre-ERT2 mouse line has also been generated 
(Mezzano et al., 2016). Loss of DP from the SAN, which houses 
the pacemaker cells of the heart, resulted in beat-to-beat defects 
associated with loss of the pacemaker complex connexin, Cx45. 
Notably, no changes in Cx45 transcript level were detected, rais-
ing the possibility that Cx45 protein levels are regulated post-
translationally. Although Cx45 has been demonstrated to be a 
phosphoprotein with multiple serine residues in its C terminus, 
the exact role of Cx45 phosphorylation or the specific kinases 
that may modulate it are not known (Lampe and Lau, 2000; van 
Veen et al., 2000). Along with the data reported in this study, 
these observations raise the possibility that DP controls Cx45 
expression through modulation of specific Cx45 phosphosites 
that govern its dynamics.
The importance of Cx43 to the cardiac conduction system was 
highlighted in a recent study that implicated tissue resident mac-
rophages present in mouse and human atrioventricular nodes in 
the regulation of cardiac electrical conduction (Hulsmans et al., 
2017). The authors demonstrate that macrophages and cardiomy-
ocytes are connected by Cx43-based gap junctions, whereby the 
resident macrophages function to modulate the electrical con-
duction of cardiomyocytes (Hulsmans et al., 2017). This finding 
could have important implications for both cardiac homeostasis 
and diseases such as ACM, in which increased cytokine expres-
sion and inflammation may contribute to disease progression 
(Corrado et al., 1997; Campian et al., 2010; Sen-Chowdhry et al., 
2010; Asimaki et al., 2011).
The physiological relevance of our findings is supported by 
our analysis of cardiac tissue from a patient harboring a patho-
genic PKP2 ACM mutation, which exhibited elevated levels of 
p-Cx43 S279/282 compared with control heart, reminiscent of 
that observed in murine DPcKO hearts. This was interesting in 
light of our previous observation that loss of PKP2 in cardiac 
cells promotes DP destabilization through proteasome-medi-
ated degradation (Dubash et al., 2016). Although previous stud-
ies have shown that depletion of PKP2 resulted in defects in DP 
localization to cell junctions, effects on its protein expression 
levels appear to be exclusive to the cardiac system (Bass-Zubek 
et al., 2008; Godsel et al., 2010). This is likely because PKP2 is 
the lone isoform expressed in cardiac cells as opposed to epithe-
lial cells that express PKP1 and PKP3 (Bass-Zubek et al., 2009). 
In the same study, we demonstrated that a profibrotic signal-
ing pathway triggered by the activation of TGF-β in response 
to PKP2 depletion was caused by the secondary loss of DP. This 
finding, coupled with the present observation that a PKP2 ACM 
mutation phenocopies the effects of DP loss, suggests the possi-
bility that a portion of the pathogenic mutations in ACM asso-
ciated with PKP2 may be corollary to its effects on DP expres-
sion and its loss.
Figure 8. Model of DP dependent regulation 
of Cx43 phosphorylation and degradation. (A) 
Loss of DP leads to elevated Ras gene expression 
that results in elevated Ras activation. Activation 
of the Ras signaling pathway leads to increased 
p-ERK1/2–MAPK levels that in turn phosphor-
ylate Cx43 at S279/282. N-Cad, N-Cadherin; 
β-Cat, β-catenin; αT, αT-catenin; αE, αE-catenin; 
Dsg, Desmoglein; Dsc, Desmocollin. (B) Loss of 
DP also results in increased ubiquitination of 
Cx43. Cx43 is subsequently targeted for degra-
dation via a lysosomal pathway. Ub, Ubiquitin.
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Isolation of NRV CMs, cell culture, and mouse models
NRV CMs were isolated as previously described (Dubash et al., 
2016) from 1- to 3-d-old Sprague-Dawley rats (Charles River). 
Briefly, hearts were dissected from neonatal rats, enzymatically 
digested, and resuspended in M199 medium (Lonza) containing 
10% FBS supplemented with 15 µM vitamin B12. Cells were then 
plated for 2 h on plastic cell culture dishes to separate the cardiac 
fibroblasts that adhere more rapidly than cardiomyocytes. The 
remaining cell suspension was then filtered through a 40-µM 
filter, spun down, and resuspended in M199 medium containing 
10% horse serum, 15 µM vitamin B12, and BrdU. Plating of cells 
was then performed in six-well dishes or coverslips that had been 
coated with collagen type IV. Media was changed every 24–48 h, 
and adenoviral infection was performed 48  h after isolation. 
These protocols were conducted with the approval of the North-
western University Institutional Animal Care and Use Commit-
tee, and all animal care protocols conform to National Institutes 
of Health (NIH) guidelines and the recommendations of the 
Panel on Euthanasia of the American Veterinary Medical Associ-
ation. The HL-1 cell line was maintained with Claycomb medium 
(Sigma-Aldrich) supplemented with 10% FBS (Atlanta Biologi-
cals), 0.1 mM norepinephrine, 2 mM l-glutamine, and penicil-
lin/streptomycin solution (Sigma-Aldrich). Cells were grown on 
plastic dishes precoated with a solution of FN-0.02% gelatin.
To delete the DP gene in the mouse epidermis, conditional 
gene targeting was used whereby Exon 2 of the DP gene was 
flanked with LoxP sites and removed by breeding with mice 
transgenic for Cre recombinase under the control of the keratin 
14 promoter (Vasioukhin et al., 2001). The K14-Cre transgenic 
and the DP-floxed (DSPflox/flox) mice were gifts from E. Fuchs 
(Rockefeller University, New York, NY). Epidermis obtained from 
E18.5 embryos were snap-frozen in liquid nitrogen and either 
processed for Western blotting or sectioned for immunofluores-
cence analysis. To delete the DP gene in the mouse myocardium, 
DP-floxed mice were bred with heterozygous ventricular myosin 
light chain-2 Cre [MLC2v(cre+)] mice. DPcKO mice and their con-
trol littermates were on a congenic C56Bl/6 background. Hearts 
obtained from 8-wk-old mice were snap-frozen in liquid nitro-
gen and sectioned for immunofluorescence analysis.
DNA, siRNA, and shRNA constructs, adenovirus production, 
and chemical reagents
The DPII-GFP construct was generated with the QuikChange II 
XL site-directed mutagenesis kit (Agilent Technologies) whereby 
nucleotides 3,584–5,380 were spliced out of a GFP-tagged full-
length DPI construct (Godsel et al., 2005). Adenoviral DPII was 
generated using Gateway recombination, whereby DPII-GFP was 
cloned into the pAd CMV/V5-DEST vector. The EmGFP BLO CK-iT 
PolIII miR RNAi Expression Vector kit (Thermo Fisher Scientific) 
was used to design and generate control and rat DP-specific oli-
gonucleotides (target sequences: 5′-AAA CCG GAA ACA TCA TCT 
CTT-3′ and 5′-TGG TAA TAG TTG ACC CAG AAA-3′). These oligonu-
cleotides where then cloned into the pAd CMV/V5-DEST vector 
using Gateway recombination. Adenovirus was generated using 
the ViraPower Adenoviral Expression System (Invitrogen). K-Ras 
shRNA was generated from a rat K-Ras specific sequence within 
the lentiviral backbone pLKO (target sequence, 5′-CCG GCT ATA 
CAT TAG TCC GAG AAA TCT CGA GAT TTC TCG GAC TAA TGT ATA GTT 
TTTG-3′; Sigma-Aldrich). Lentiviral particles were generated by 
the Northwestern University Skin Disease Research Center DNA/
RNA Delivery Core. DP-specific murine siRNA oligonucleotides 
were obtained from GE Healthcare (sense sequences: 5′-GUG 
CAG AAC UUG GUA AACA-3′ and 5′-GCA UCC AGC UUC AGA CAAA-
3′). Cells were treated with the following reagents at the stated 
concentrations: 10 µg/ml cycloheximide, 100 µM chloroquine, 
10 µM MG132, 5 µM U0126, and 2 nM RRSP.
Transfections
Transient transfections were performed using DharmaFECT 
(GE Healthcare). Cells plated at 60–70% confluence were incu-
bated with 0.2–5 µg DNA and DharmaFECT reagent premixed in 
serum-free media. Fresh medium was added 24 h after transfec-
tion, and samples were lysed or fixed 72 h after transfection.
Antibodies
The following primary antibodies were used in this study: NW6 
rabbit anti-DP directed against the C-terminal domain of DP 
(Angst et al., 1990), 1407 chicken anti-Pg (Aves Laboratories), 
mouse anti-PKP2 (651101; Progen), 115F mouse anti-DP (a gift from 
D. Garrod, University of Manchester, Manchester, UK), 12G10 
mouse anti–α-tubulin (Developmental Studies Hybridoma Bank), 
rabbit anti-Cx43 (AB1728; EMD Millipore), mouse anti-Cx43 
(MAB3068; EMD Millipore), IF1 mouse anti-Cx43 (P. Lampe, Fred 
Hutchinson Research Center, Seattle, WA), mouse anti–N-cad-
herin (Invitrogen), mouse anti–α-catenin, rabbit anti–β-catenin 
(C2206; Sigma-Aldrich), mouse anti-Vinculin (V9131; Sigma-Al-
drich), rabbit anti–phospho-Cx43 S279/282 (sc-12900-R; Santa 
Cruz Biotechnology), rabbit anti–phospho-Cx43 S279/282 (P. 
Lampe), rabbit anti–p-44/42 (9101; Cell Signaling Technologies), 
rabbit anti–total 44/42 (V1141; Promega), FK2 mouse anti–ubiq-
uitylated proteins (04-263; EMD Millipore), 1296 anti-Myosin 
VI (S. Polo, FIRC Institute of Molecular Oncology, Milan, Italy), 
mouse anti–K-ras (WH0003845M1; Sigma-Aldrich), and mouse 
anti–Ras-GTP (26909; NewEast Biosciences). Peroxidase-conju-
gated anti–mouse, –rabbit, and –chicken secondary antibodies 
were used for Western blot analysis (Kiekegaard & Perry Labo-
ratories). Alexa Fluor 488/568/647–conjugated goat anti–mouse, 
–rabbit, and –chicken secondary antibodies were used for immu-
nofluorescence assays (Invitrogen).
Western blotting and coimmunoprecipitation assays
For analysis of protein expression levels, cells were washed once 
with PBS and lysed in urea sample buffer (8 M deionized urea, 
1% sodium dodecyl sulfate, 10% glycerol, 60  mM Tris, pH 6.8, 
and 5% β-mercaptoethanol). Total protein concentrations were 
equalized, and samples were run on 7.5–12% SDS-PAGE gels. 
Gels were transferred to polyvinylidene fluoride membranes to 
be probed with primary and secondary antibodies against pro-
teins of interest.
Cells used for coimmunoprecipitation assays were washed 
twice with PBS and lysed with modified RIPA buffer (500 mM 
NaCl, 50 mM Tris, pH 7.6, 10 mM MgCl2, 1% Triton X-100, 0.1% 
SDS, and 0.5% deoxycholate) supplemented with complete 
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protease inhibitor cocktail (Roche). Samples were then incubated 
with 1 µg antibody against the protein of interest to be pulled 
down by rotating overnight at 4°C. Subsequently, samples were 
incubated with Protein A/G PLUS Agarose beads (Santa Cruz Bio-
technology) for 30 min at 4°C. Samples were washed and eluted 
in Laemmli buffer with 5% β-mercaptoethanol, followed by SDS-
PAGE and Western blot analysis.
PLA
Reagents required for PLA analysis were purchased from Sig-
ma-Aldrich. Cells were rinsed and fixed as described for conven-
tional immunofluorescence. Samples were then incubated with 
primary antibodies for the proteins of interest for 1 h at 37°C fol-
lowed by incubation with secondary PLA probes for 1 h at 37°C. 
This was followed by a 30-min incubation with PLA ligase for 
ligation of nucleotides on corresponding probes. Subsequently, 
PLA polymerase was added for 100 min at 37°C to amplify the PLA 
signal, which results in red fluorescent dots if the antigens in 
question are in close proximity. Samples were mounted with PLA 
mounting medium containing DAPI, and ImageJ software (NIH) 
was used to quantify the number of PLA dots, which were then 
normalized to DAPI.
qPCR
Total RNA was isolated from cells using the RNeasy Mini kit 
(Qiagen) according to the manufacturer’s instructions. Samples 
were then equalized for total RNA concentration, and cDNA was 
synthesized using the Superscript III First Strand kit (Invitro-
gen) according to the manufacturer’s instructions. qPCR was 
performed using SYBR Green PCR master mix (Applied Bio-
systems) along with the appropriate primers using a StepOne-
Plus instrument (Applied Biosystems). Calculations for relative 
mRNA levels were performed using the ΔΔCt method using levels 
of GAP DH mRNA as a control. Relative levels were presented as 
fold-change values compared with control samples. Two-tailed 
Student’s t test was used to perform statistical analysis, with P 
values <0.05 considered statistically significant.
Immunofluorescence and quantification of pixel intensity
Cells grown on glass coverslips were washed once with PBS and 
fixed using 4% PFA or ice-cold methanol. Cells were then per-
meabilized with 0.2% Triton X-100 in PBS. Primary antibodies 
were added to coverslips and incubated at 37°C for 1 h followed 
by multiple washes in PBS. Alexa Fluor secondary antibodies 
(Thermo Fisher Scientific) were added and incubated for 30 min, 
followed by PBS washes and mounting of coverslips in polyvinyl 
alcohol (Sigma-Aldrich). Samples were visualized using a DMR 
microscope (Leica Microsystems) fitted with 40-Å (NA 1.0, Plan 
Fluotar) and 63-Å (NA 1.32, Plan Apochromat) objective lenses, 
and images were captured with an Orca 100 charge-coupled 
device camera (model C4742-95; Hamamatsu Photonics) and 
MetaMorph 7.7 imaging software (Molecular Devices). Mean flu-
orescence pixel intensity was quantified using raw, unsaturated 
12-bit images with line or area tracing as stated using ImageJ. For 
quantification of junctional/ID fluorescence intensity, cell bor-
ders as marked by Pg signal using ImageJ line tracing and fluo-
rescence intensity of Pg and the costained protein were assessed 
from the same line position. Subsequently, signal intensity val-
ues of the protein of interest were normalized to Pg intensity.
Immunohistochemistry
Tissue samples were fixed in 10% neutral-buffered formalin 
and embedded in paraffin. Paraffin-embedded sections were 
deparaffinized in sequential xylene and ethanol washes. Anti-
gen retrieval for paraffin-embedded sections was performed by 
heating samples to 95°C in 0.01 M citrate buffer. Sections were 
blocked in 10% normal goat serum and incubated with primary 
and secondary antibodies for 1 h at 37°C. After mounting in poly-
vinyl alcohol, sections were visualized as described above.
Surface biotinylation assay
Cells were washed twice with ice-cold PBS and incubated with 2 
mg/ml EZ-Link Sulfo-NHS-SS-biotin (Thermo Fisher Scientific) 
for 30 min at 4°C. Excess biotin was quenched with 100 mM gly-
cine in PBS by washing three times for 10 min each. Cells were 
then washed with PBS and lysed in RIPA buffer (10  mM Tris, 
pH 7.5, 140 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium 
deoxycholate, 5 mM EDTA, 2 mM EGTA, and complete protease 
inhibitor). Lysates were centrifuged, and cell supernatants were 
normalized for total protein. 30 µl whole cell lysate was saved 
for input controls. Streptavidin beads (Thermo Fisher Scientific) 
were then used to pull down biotinylated proteins by rotating 
overnight at 4°C. After several washes in lysis buffer, samples 
were eluted using Laemmli sample buffer at 95°C and analyzed 
by Western blot as described above.
Scrape loading dye transfer assay
Cells were grown to confluence on glass coverslips and treated 
with appropriate KD conditions. A surgical blade was used to 
scrape lines in the confluent monolayer. Medium was aspirated 
and replaced with cell culture media premixed with 100 µl LY at 
12 mg/ml stock (Thermo Fisher Scientific). Cells were incubated 
at 37°C for 15 min followed by PBS washes. Subsequently, samples 
were fixed in PFA and processed for immunofluorescence anal-
ysis as described above.
Delivery of RRSP into cells
NRV CMs seeded onto either six-well plates or glass covers-
lips were treated with the appropriate adenoviral constructs. 
Purification and cellular intoxication with LFN DUF5Vv and 
PA (referred to simply as RRSP) were conducted as previously 
described previously (Antic et al., 2015). Before treatment, cells 
in culture were provided with fresh medium. Next, 4.6 nM PA 
and 2 nM RRSP were added to the media for overnight incuba-
tion. Cells were either lysed in appropriate lysis buffer for West-
ern blot analysis or fixed for image processing.
Statistics
All quantifications are presented as the mean ± SD. One-way 
ANO VA followed by Tukey’s post hoc analysis or Dunnett’s mul-
tiple comparison test was used for multiple comparisons. For 
data comparing two conditions, statistical differences were ana-
lyzed with a two-tailed Student’s t test. P < 0.05 was considered 
significant. For statistical analysis presented as fold change (bar 
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graphs), the mean of data from control samples was assigned 
a value of 1, and all other samples were calculated relative to 
the control. All densitometry quantification was normalized to 
respective loading controls.
Study approval
For the DPeKO mouse model, all mice were housed in accredited 
animal facilities, and the use and care of mice were in accordance 
with Northwestern University’s Institutional Care and Use Com-
mittee. For the DPcKO mouse model, all animal procedures were 
in full compliance with the guidelines approved by the Univer-
sity of California, San Diego, Animal Care and Use Committee. 
For human samples, informed consent was not required for the 
experiments performed in this study as all human samples were 
obtained as deidentified tissue and are covered by Beth Israel 
Deaconess Medical Center exemption protocols.
Online supplemental material
Fig. S1 shows that tissue sections from two independent DP ACM 
patients display a complete loss of DP and Cx43 localization at 
IDs. Fig. S2 demonstrates that depletion of DP in NRV CMs does 
not result in a significant change in Cx43 transcript levels. Fig. 
S3 shows that dose-dependent addition of RRSP to NRV CMs 
results in corresponding inhibition of p-ERK1/2 signal. Fig. S4 
demonstrates that DPeKO epidermis does not display a signif-
icant change in KRAS, HRAS, or NRAS mRNA levels compared 
with WT tissue.
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Figure S1. DP ACM patients display complete loss of Cx43 expression. (A) Patient cardiac sections harboring the mutations 1,218+1 G->A (DP ACM #1) 
and C3337T (DP AC #2) and control tissue were stained for total Cx43 (n = 1). ACM patients showed loss of Cx43 expression from IDs. White arrowheads 
denote areas with positive lipofuscin staining. (B) Control and DP ACM patient cardiac sections were stained for DP and Pg as a marker of IDs (n = 1). Bars, 
20 µm. Both DP ACM patients show loss of DP from IDs. (B′) Quantification of DP ID intensity normalized to Pg in control and DP ACM patient samples. Error 
bars represent mean ± SD. ****, P < 0.0001 by one-way ANO VA followed by Dunnett’s multiple comparison test.
Figure S2. Loss of DP does not cause a significant change in Cx43 mRNA levels. NRV CMs treated with control or DP shRNA were processed for qPCR 
analysis (n = 3). KD of DP did not lead to a significant change in Cx43 transcript levels by two-tailed Student’s t test. Error bars represent mean ± SD.
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Figure S3. RRSP treatment is sufficient to inhibit ERK1/2 signaling in NRV CMs. NRV CMs were treated with the indicated concentrations of RRSP over-
night and then processed for Western blot analysis (n = 3). Samples were blotted for p-ERK1/2 and pan Ras with tubulin as a loading control.
Figure S4. Ras transcript levels are unaffected in DP null epidermis. WT and DPeKO samples were processed for qPCR and analyzed for KRAS, HRAS, 
and NRAS mRNA levels (n = 3). The transcript levels of all three Ras isoforms were not significantly changed between WT and DPeKO samples as assessed 
by two-tailed Student’s t test. Error bars represent mean ± SD.
